Literature DB >> 18185500

Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis.

Deepak Cyril D'Souza1, Mohini Ranganathan, Gabriel Braley, Ralitza Gueorguieva, Zoran Zimolo, Thomas Cooper, Edward Perry, John Krystal.   

Abstract

Cannabis is one of the most widely used illicit substances and there is growing interest in the association between cannabis use and psychosis. Delta-9-Tetrahydrocannabinol (Delta-9-THC) the principal active ingredient of cannabis has been shown to induce psychotomimetic and amnestic effects in healthy individuals. Whether people who frequently use cannabis are either protected from or are tolerant to these effects of Delta-9-THC has not been established. In a 3-day, double-blind, randomized, placebo-controlled study, the dose-related effects of 0, 2.5, and 5 mg intravenous Delta-9-THC were studied in 30 frequent users of cannabis and compared to 22 healthy controls. Delta-9-THC (1) produced transient psychotomimetic effects and perceptual alterations; (2) impaired memory and attention; (3) increased subjective effects of 'high'; (4) produced tachycardia; and (5) increased serum cortisol in both groups. However, relative to controls, frequent users showed blunted responses to the psychotomimetic, perceptual altering, cognitive impairing, anxiogenic, and cortisol increasing effects of Delta-9-THC but not to its euphoric effects. Frequent users also had lower prolactin levels. These data suggest that frequent users of cannabis are either inherently blunted in their response to, and/or develop tolerance to the psychotomimetic, perceptual altering, amnestic, endocrine, and other effects of cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18185500      PMCID: PMC3799954          DOI: 10.1038/sj.npp.1301643

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  66 in total

Review 1.  From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis.

Authors:  R Mechoulam; S Ben-Shabat
Journal:  Nat Prod Rep       Date:  1999-04       Impact factor: 13.423

2.  Testing the level of response to alcohol: social information processing model of alcoholism risk--a 20-year prospective study.

Authors:  Marc A Schuckit; Tom L Smith; Kristen G Anderson; Sandra A Brown
Journal:  Alcohol Clin Exp Res       Date:  2004-12       Impact factor: 3.455

3.  The environment and schizophrenia: the role of cannabis use.

Authors:  Cécile Henquet; Robin Murray; Don Linszen; Jim van Os
Journal:  Schizophr Bull       Date:  2005-06-23       Impact factor: 9.306

Review 4.  United States epidemiologic data on drug use and abuse: how are they relevant to testing abuse liability of drugs?

Authors:  J C Anthony; A M Trinkoff
Journal:  NIDA Res Monogr       Date:  1989

Review 5.  Cannabis use and psychotic disorders: an update.

Authors:  Wayne Hall; Louisa Degenhardt; Maree Teesson
Journal:  Drug Alcohol Rev       Date:  2004-12

Review 6.  Cannabis-associated psychosis: current status of research.

Authors:  F Markus Leweke; Christoph W Gerth; Joachim Klosterkötter
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Cannabinoid tolerance and dependence: a review of studies in laboratory animals.

Authors:  Sara González; Maribel Cebeira; Javier Fernández-Ruiz
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

Review 8.  Cannabis--1988.

Authors:  L E Hollister
Journal:  Acta Psychiatr Scand Suppl       Date:  1988

9.  Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction.

Authors:  Avshalom Caspi; Terrie E Moffitt; Mary Cannon; Joseph McClay; Robin Murray; HonaLee Harrington; Alan Taylor; Louise Arseneault; Ben Williams; Antony Braithwaite; Richie Poulton; Ian W Craig
Journal:  Biol Psychiatry       Date:  2005-05-15       Impact factor: 13.382

Review 10.  Interpreting the association between cannabis use and increased risk for schizophrenia.

Authors:  Mark Weiser; Shlomo Noy
Journal:  Dialogues Clin Neurosci       Date:  2005       Impact factor: 5.986

View more
  97 in total

Review 1.  Endocannabinoids and the Endocrine System in Health and Disease.

Authors:  Cecilia J Hillard
Journal:  Handb Exp Pharmacol       Date:  2015

2.  Neurocognitive functioning of individuals with schizophrenia: using and not using drugs.

Authors:  Amber L Bahorik; Christina E Newhill; Shaun M Eack
Journal:  Schizophr Bull       Date:  2013-07-24       Impact factor: 9.306

3.  Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice.

Authors:  Caitlin M Nealon; Angela N Henderson-Redmond; David E Hale; Daniel J Morgan
Journal:  Neuropharmacology       Date:  2019-01-08       Impact factor: 5.250

Review 4.  The endocannabinoid system as a target for modelling psychosis.

Authors:  Dagmar Koethe; Carolin Hoyer; F Markus Leweke
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

5.  Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans.

Authors:  Deepak Cyril D'Souza; Brian Pittman; Edward Perry; Arthur Simen
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

6.  Psychobiological responses to unpleasant emotions in cannabis users.

Authors:  Lorenzo Somaini; Matteo Manfredini; Mario Amore; Amir Zaimovic; Maria Augusta Raggi; Claudio Leonardi; Maria Lidia Gerra; Claudia Donnini; Gilberto Gerra
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-07-20       Impact factor: 5.270

Review 7.  The why behind the high: determinants of neurocognition during acute cannabis exposure.

Authors:  Johannes G Ramaekers; Natasha L Mason; Lilian Kloft; Eef L Theunissen
Journal:  Nat Rev Neurosci       Date:  2021-05-27       Impact factor: 34.870

8.  ΔFosB induction correlates inversely with CB₁ receptor desensitization in a brain region-dependent manner following repeated Δ⁹-THC administration.

Authors:  Matthew F Lazenka; Dana E Selley; Laura J Sim-Selley
Journal:  Neuropharmacology       Date:  2013-09-30       Impact factor: 5.250

9.  Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans.

Authors:  Michael E Ballard; David A Gallo; Harriet de Wit
Journal:  Psychopharmacology (Berl)       Date:  2012-12-09       Impact factor: 4.530

10.  Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

Authors:  Matthew F Lazenka; Bethany G David; Aron H Lichtman; Eric J Nestler; Dana E Selley; Laura J Sim-Selley
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.